Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines

Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide‐conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells, where it is converted to the known alkylator melphalan leading...

Descripción completa

Detalles Bibliográficos
Autores principales: Schepsky, Alexander, Traustadottir, Gunnhildur Asta, Joelsson, Jon Petur, Ingthorsson, Sævar, Kricker, Jennifer, Bergthorsson, Jon Thor, Asbjarnarson, Arni, Gudjonsson, Thorkell, Nupponen, Nina, Slipicevic, Ana, Lehmann, Fredrik, Gudjonsson, Thorarinn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520280/
https://www.ncbi.nlm.nih.gov/pubmed/32717133
http://dx.doi.org/10.1002/cam4.3300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520280/
https://www.ncbi.nlm.nih.gov/pubmed/32717133
http://dx.doi.org/10.1002/cam4.3300

Ejemplares similares